These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 29752388)

  • 1. Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation).
    Zhang Z; Jones P; Weintraub WS; Mancini GBJ; Sedlis S; Maron DJ; Teo K; Hartigan P; Kostuk W; Berman D; Boden WE; Spertus JA
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003971. PubMed ID: 29752388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
    Spertus JA; Maron DJ; Cohen DJ; Kolm P; Hartigan P; Weintraub WS; Berman DS; Teo KK; Shaw LJ; Sedlis SP; Knudtson M; Aslan M; Dada M; Boden WE; Mancini GB;
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):409-18. PubMed ID: 23838107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.
    Al-Lamee R; Howard JP; Shun-Shin MJ; Thompson D; Dehbi HM; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik IS; Cook C; Ahmad Y; Sharp ASP; Gerber R; Baker C; Kaprielian R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom SA; Davies JE; Francis DP
    Circulation; 2018 Oct; 138(17):1780-1792. PubMed ID: 29789302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina.
    Zhang Z; Kolm P; Boden WE; Hartigan PM; Maron DJ; Spertus JA; O'Rourke RA; Shaw LJ; Sedlis SP; Mancini GB; Berman DS; Dada M; Teo KK; Weintraub WS
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):172-82. PubMed ID: 21304091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial).
    Bradley SM; Chan PS; Hartigan PM; Nallamothu BK; Weintraub WS; Sedlis SP; Dada M; Maron DJ; Kostuk WJ; Berman DS; Teo KK; Mancini GB; Boden WE; Spertus JA
    Am J Cardiol; 2015 Jul; 116(2):167-73. PubMed ID: 25960375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.
    Mancini GBJ; Boden WE; Brooks MM; Vlachos H; Chaitman BR; Frye R; Bittner V; Hartigan PM; Dagenais GR
    Atherosclerosis; 2018 Oct; 277():186-194. PubMed ID: 29861270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).
    Sedlis SP; Jurkovitz CT; Hartigan PM; Kolm P; Goldfarb DS; Lorin JD; Dada M; Maron DJ; Spertus JA; Mancini GB; Teo KK; Boden WE; Weintraub WS;
    Am J Cardiol; 2013 Dec; 112(11):1703-8. PubMed ID: 24011740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.
    Teo KK; Sedlis SP; Boden WE; O'Rourke RA; Maron DJ; Hartigan PM; Dada M; Gupta V; Spertus JA; Kostuk WJ; Berman DS; Shaw LJ; Chaitman BR; Mancini GB; Weintraub WS;
    J Am Coll Cardiol; 2009 Sep; 54(14):1303-8. PubMed ID: 19778673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.
    Shaw LJ; Berman DS; Maron DJ; Mancini GB; Hayes SW; Hartigan PM; Weintraub WS; O'Rourke RA; Dada M; Spertus JA; Chaitman BR; Friedman J; Slomka P; Heller GV; Germano G; Gosselin G; Berger P; Kostuk WJ; Schwartz RG; Knudtson M; Veledar E; Bates ER; McCallister B; Teo KK; Boden WE;
    Circulation; 2008 Mar; 117(10):1283-91. PubMed ID: 18268144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCI Choice Decision Aid for Stable Coronary Artery Disease: A Randomized Trial.
    Coylewright M; Dick S; Zmolek B; Askelin J; Hawkins E; Branda M; Inselman JW; Zeballos-Palacios C; Shah ND; Hess EP; LeBlanc A; Montori VM; Ting HH
    Circ Cardiovasc Qual Outcomes; 2016 Nov; 9(6):767-776. PubMed ID: 27803090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, triple-blind trial of cardiac shock-wave therapy on exercise tolerance and symptoms in patients with stable angina pectoris.
    Shkolnik E; Burneikaite G; Jakutis G; Scherbak M; Zuoziene G; Petrauskiene B; Trush E; Vasyuk Y; Laucevicius A; Celutkiene J
    Coron Artery Dis; 2018 Nov; 29(7):579-586. PubMed ID: 29912782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical outcomes following percutaneous coronary intervention versus optimal medical therapy based on gray-zone fractional flow reserve in stable angina patients with intermediate coronary artery stenosis (COMFORTABLE prospective study): Study protocol for a multicenter randomized controlled trial.
    Kitabata H; Kubo T; Shiono Y; Shimamura K; Ino Y; Tanimoto T; Hayashi Y; Komukai K; Sougawa H; Kimura K; Gohda M; Hashizume T; Obana M; Maeda K; Yamaguchi J; Akasaka T
    Trials; 2019 Jan; 20(1):84. PubMed ID: 30691507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial.
    Hennigan B; Berry C; Collison D; Corcoran D; Eteiba H; Good R; McEntegart M; Watkins S; McClure JD; Mangion K; Ford TJ; Petrie MC; Hood S; Rocchiccioli P; Shaukat A; Lindsay M; Oldroyd KG
    Heart; 2020 May; 106(10):758-764. PubMed ID: 32114516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractional Flow Reserve and Quality-of-Life Improvement After Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease.
    Nishi T; Piroth Z; De Bruyne B; Jagic N; Möbius-Winkler S; Kobayashi Y; Derimay F; Fournier S; Barbato E; Tonino P; Jüni P; Pijls NHJ; Fearon WF
    Circulation; 2018 Oct; 138(17):1797-1804. PubMed ID: 30354650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial.
    Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM
    Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial).
    Padala SK; Sidhu MS; Hartigan PM; Maron DJ; Teo KK; Spertus JA; Mancini GB; Sedlis SP; Chaitman BR; Heller GV; Weintraub WS; Boden WE
    Am J Cardiol; 2015 Nov; 116(10):1509-15. PubMed ID: 26410604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of PCI on quality of life in patients with stable coronary disease.
    Weintraub WS; Spertus JA; Kolm P; Maron DJ; Zhang Z; Jurkovitz C; Zhang W; Hartigan PM; Lewis C; Veledar E; Bowen J; Dunbar SB; Deaton C; Kaufman S; O'Rourke RA; Goeree R; Barnett PG; Teo KK; Boden WE; ; Mancini GB
    N Engl J Med; 2008 Aug; 359(7):677-87. PubMed ID: 18703470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia.
    Mancini GBJ; Hartigan PM; Shaw LJ; Berman DS; Hayes SW; Bates ER; Maron DJ; Teo K; Sedlis SP; Chaitman BR; Weintraub WS; Spertus JA; Kostuk WJ; Dada M; Booth DC; Boden WE
    JACC Cardiovasc Interv; 2014 Feb; 7(2):195-201. PubMed ID: 24440015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal medical therapy and percutaneous coronary intervention for stable angina: why patients should 'be taking' and 'keep taking' the tablets.
    Mohee K; Wheatcroft SB
    J Clin Pharm Ther; 2014 Aug; 39(4):331-3. PubMed ID: 24754310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease: Three-Year Follow-Up of the FAME 2 Trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation).
    Fearon WF; Nishi T; De Bruyne B; Boothroyd DB; Barbato E; Tonino P; Jüni P; Pijls NHJ; Hlatky MA;
    Circulation; 2018 Jan; 137(5):480-487. PubMed ID: 29097450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.